Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Neumeister

Showing results (11-20 of 90) with videos related to

Pageof 9
Sort By:
Platelets|November 20, 2013
Assessment of the response to acetylsalicylic acid in patients with myeloproliferative neoplasms by whole blood assays: a comparison of the PFA-100 with multiple electrode aggregometryChristoph Robier, Manfred Neubauer, Franz Quehenberger, et al.
Current Drug Targets|November 21, 2014
The nuclear orphan receptor NR4A1 and NR4A3 as tumor suppressors in hematologic neoplasmsKerstin Wenzl, Katharina Troppan, Peter Neumeister, et al.
Mycoses|November 8, 2017
Real-world challenges and unmet needs in the diagnosis and treatment of suspected invasive pulmonary aspergillosis in patients with haematological diseases: An illustrative case studyMartin Hoenigl, Juergen Prattes, Peter Neumeister, et al.
Physical Chemistry Chemical Physics : PCCP|September 22, 2020
Pyrocatalytic oxidation - strong size-dependent poling effect on catalytic activity of pyroelectric BaTiO<sub>3</sub> nano- and microparticlesSascha Raufeisen, Peter Neumeister, Johannes R Buchheim, et al.
The International Journal of Biochemistry & Cell Biology|August 30, 2002
Senescence and epigenetic dysregulation in cancerPeter Neumeister, Chris Albanese, Beate Balent, et al.
Haematologica|August 26, 2003
Durable molecular response to imatinib mesylate following nonmyeloablative allogeneic stem-cell transplantation for persisting myeloid blast crisis in chronic myeloid leukemiaPhilipp B Staber, Ruth Brezinschek, Werner Linkesch, et al.
Anti-Cancer Agents in Medicinal Chemistry|May 16, 2012
The nuclear orphan receptors NR4A as therapeutic target in cancer therapyAlexander J A Deutsch, Hannes Angerer, Tamara E Fuchs, et al.
International Journal of Molecular Sciences|July 27, 2022
Targeting the Microenvironment for Treating Multiple MyelomaPeter Neumeister, Eduard Schulz, Katrin Pansy, et al.
Thrombosis Research|July 16, 2010
Evaluation of platelet function and pharmacological platelet inhibition in patients with myeloproliferative disorders using multiple electrode aggregometryChristoph Robier, Manfred Neubauer, Heinz Sternad, et al.
Leukemia & Lymphoma|October 22, 2013
Safety and tolerability of intrathecal liposomal cytarabine as central nervous system prophylaxis in patients with acute lymphoblastic leukemiaAngelika Valentin, Katharina Troppan, Michael Pfeilstöcker, et al.
Pageof 9

Showing results (11-20 of 90) with videos related to

Sort By:
Pageof 9
Platelets|November 20, 2013
Assessment of the response to acetylsalicylic acid in patients with myeloproliferative neoplasms by whole blood assays: a comparison of the PFA-100 with multiple electrode aggregometryChristoph Robier, Manfred Neubauer, Franz Quehenberger, et al.
Current Drug Targets|November 21, 2014
The nuclear orphan receptor NR4A1 and NR4A3 as tumor suppressors in hematologic neoplasmsKerstin Wenzl, Katharina Troppan, Peter Neumeister, et al.
Mycoses|November 8, 2017
Real-world challenges and unmet needs in the diagnosis and treatment of suspected invasive pulmonary aspergillosis in patients with haematological diseases: An illustrative case studyMartin Hoenigl, Juergen Prattes, Peter Neumeister, et al.
Physical Chemistry Chemical Physics : PCCP|September 22, 2020
Pyrocatalytic oxidation - strong size-dependent poling effect on catalytic activity of pyroelectric BaTiO<sub>3</sub> nano- and microparticlesSascha Raufeisen, Peter Neumeister, Johannes R Buchheim, et al.
The International Journal of Biochemistry & Cell Biology|August 30, 2002
Senescence and epigenetic dysregulation in cancerPeter Neumeister, Chris Albanese, Beate Balent, et al.
Haematologica|August 26, 2003
Durable molecular response to imatinib mesylate following nonmyeloablative allogeneic stem-cell transplantation for persisting myeloid blast crisis in chronic myeloid leukemiaPhilipp B Staber, Ruth Brezinschek, Werner Linkesch, et al.
Anti-Cancer Agents in Medicinal Chemistry|May 16, 2012
The nuclear orphan receptors NR4A as therapeutic target in cancer therapyAlexander J A Deutsch, Hannes Angerer, Tamara E Fuchs, et al.
International Journal of Molecular Sciences|July 27, 2022
Targeting the Microenvironment for Treating Multiple MyelomaPeter Neumeister, Eduard Schulz, Katrin Pansy, et al.
Thrombosis Research|July 16, 2010
Evaluation of platelet function and pharmacological platelet inhibition in patients with myeloproliferative disorders using multiple electrode aggregometryChristoph Robier, Manfred Neubauer, Heinz Sternad, et al.
Leukemia & Lymphoma|October 22, 2013
Safety and tolerability of intrathecal liposomal cytarabine as central nervous system prophylaxis in patients with acute lymphoblastic leukemiaAngelika Valentin, Katharina Troppan, Michael Pfeilstöcker, et al.
Pageof 9